返回
摘要
En
期刊
IF:
23.1
论文数:
5.4K
被引数:
16.6W
机构
引用论文
Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia核心结合因子急性髓系白血病中强化诱导方案的现况结局
eJHaem
IF0
A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia
Blood
IF23.1
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801
BLOOD ADVANCES
IF7.1
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials在急性髓系白血病成人患者诱导化疗中添加gemtuzumab ozogamicin:一项基于随机对照试验个体患者数据的meta分析
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemiavenetoclax联合FLAG-IDA诱导和巩固治疗新诊断和复发或难治性急性髓系白血病的长期结果
LEUKEMIA
IF13.4
The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment
BLOOD REVIEWS
IF5.7
Fusion Gene Depletion Eliminates Stemness and Induces Bidirectional Differentiation of Acute Myeloid Leukemia融合基因耗竭消除急性髓系白血病的干性并诱导其双向分化
Blood
IF23.1
没有更多内容

